Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Synlogic Links Up With AbbVie For IBD Microbiome Therapies

This article was originally published in Scrip

Executive Summary

Synlogic Inc., focused on the intersection of synthetic biology and microbiome therapeutics, signed its first partnership Feb. 10, agreeing to a multi-year collaboration with AbbVie Inc. to develop what it calls "synthetic biotic" therapies for Crohn's disease and ulcerative colitis.

You may also be interested in...



Deal Watch: Chinook To Go Public Via Reverse Merger With Troubled Aduro

Focused on precision medicine for renal disease, Chinook gets Aduro’s Nasdaq listing and starting capital of $200m. During a wave of modest-sized M&A deals, Tetra finds buyer, Tetraphase gets competing bids.

Synlogic Pivots After First Clinical Failure

The synthetic biotics company is discontinuing development of SNYB1020, its first clinical-stage product, which failed to lower blood ammonia in cirrhosis patients.

Synlogic Moves Synthetic Biotics To The Clinic For Rare Metabolic Disease

Emerging Company Profile: Pioneering the development of a new class of living medicines that work in the microbiome, Synlogic completed a reverse merger earlier this year that took the company public.

Related Content

Topics

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel